Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ:AMGN) announced positive topline results from its Phase 3 FORTITUDE-101 clinical trial for bemarituzumab in gastric cancer treatment. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in overall survival (OS) when combining bemarituzumab with chemotherapy compared to placebo plus chemotherapy.
The study focused on patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and non-HER2 positive status. This breakthrough is particularly significant given that gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths annually.
The most common treatment-emergent adverse events included reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye. Notably, ocular events occurred with greater frequency and severity in the bemarituzumab arm compared to the Phase 2 experience. A separate Phase 3 study combining bemarituzumab with chemotherapy and nivolumab is ongoing, with results expected in H2 2025.
Amgen (NASDAQ:AMGN) has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. Kave Niksefat, senior vice president of Global Marketing and Access, will represent the company at the event scheduled for Wednesday, May 21, 2025, at 9:00 a.m. ET.
The presentation will be accessible via webcast to investors, media, and the general public through Amgen's website (www.amgen.com) under the Investors section. The webcast recording will remain available for replay for a minimum of 90 days following the event.